Literature DB >> 9679207

Educating patients about the benefits and drawbacks of hormone replacement therapy.

S Rozenberg1, J B Vasquez, J Vandromme, M Kroll.   

Abstract

Hormone replacement therapy (HRT) influences many aspects of health: climacteric symptoms, osteoporosis, cardiovascular disease, breast and endometrial cancer, thrombosis and emboli, and Alzheimer's disease. A decision to use HRT may depend on a woman's individual views of the menopausal transition, the postmenopause and its consequences. It is therefore useful that the health provider inquiries about and discusses these issues in a cultural and family context. Health providers and patients should be thoroughly informed about the symptoms associated with hormonal deprivation, the associated risks of osteoporosis and cardiovascular disease, and the potential of HRT to prevent these afflictions. Recent studies suggest that HRT might be particularly beneficial in women who have an increased risk for cardiovascular disease (because of left ventricular hypertrophy, diabetes mellitus, hypertension or hypercholesterolaemia, or because they smoke) or osteoporosis. In women who are undecided about HRT, a low bone mineral density measurement might help convince them to start using, or to continue using, HRT. There is also a need to discuss with the patient the effect of HRT on cancer risk. In most instances, women can be reassured about the risk of endometrial cancer. The risk of breast cancer should be carefully considered and discussed with each patient before beginning HRT. In most cases, HRT should not be withheld because of fears about breast cancer, because the protective effects of HRT against cardiovascular disease and osteoporosis outweigh the possible increased risk of breast cancer. When HRT is prescribed, individual regiments should be discussed with the patient, who must be warned of the possible adverse effects. In older women, HRT can be started at half the normal dosage and tolerability assessed before increasing the dosage further.

Entities:  

Mesh:

Year:  1998        PMID: 9679207     DOI: 10.2165/00002512-199813010-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  45 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer.

Authors:  L F Voigt; N S Weiss; J Chu; J R Daling; B McKnight; G van Belle
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

3.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

Authors:  K K Steinberg; S B Thacker; S J Smith; D F Stroup; M M Zack; W D Flanders; R L Berkelman
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

Review 4.  Menopause. Health promotion opportunities for the occupational health nurse.

Authors:  V L Millonig
Journal:  AAOHN J       Date:  1996-12

5.  Results of bone densitometry affect women's decisions about taking measures to prevent fractures.

Authors:  S M Rubin; S R Cummings
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

6.  Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?

Authors:  W F Posthuma; R G Westendorp; J P Vandenbroucke
Journal:  BMJ       Date:  1994-05-14

7.  Selection to postmenopausal therapy by women's characteristics.

Authors:  E Hemminki; M Malin; P Topo
Journal:  J Clin Epidemiol       Date:  1993-03       Impact factor: 6.437

8.  Cross-national study of women's use of hormone replacement therapy (HRT) in Europe.

Authors:  H P Schneider
Journal:  Int J Fertil Womens Med       Date:  1997

Review 9.  Compliance to hormone replacement therapy.

Authors:  S Rozenberg; J Vandromme; M Kroll; A Pastijn; F Liebens
Journal:  Int J Fertil Menopausal Stud       Date:  1995

Review 10.  HRT management: the American experience.

Authors:  B R Carr
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1996-04       Impact factor: 2.435

View more
  5 in total

1.  Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.

Authors:  J M Plumb; J F Guest
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 2.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 3.  Estradiol-intranasal: a review of its use in the management of menopause.

Authors:  M Dooley; C M Spencer; D Ormrod
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  [Patient education in rheumatologic care--a review].

Authors:  E Genth
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

5.  Conjugated linoleic acid prompts bone formation in ovariectomized osteoporotic rats and weakens osteoclast formation after treatment with ultraviolet B.

Authors:  Zhongshu Shan; Yanyan Zhao; Zhixue Qiu; Suonan Angxiu; Yong Gu; Junming Luo; Hongtao Bi; Wei Luo; Rui Xiong; Siqing Ma; Zhao He; Liang Chen
Journal:  Ann Transl Med       Date:  2021-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.